Schmidt P J Investment Management Inc. Sells 3,138 Shares of Thermo Fisher Scientific Inc. $TMO

Schmidt P J Investment Management Inc. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 71.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 1,248 shares of the medical research company’s stock after selling 3,138 shares during the period. Schmidt P J Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $605,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the company. Highline Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 126.9% in the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after buying an additional 33 shares in the last quarter. Capital A Wealth Management LLC increased its stake in Thermo Fisher Scientific by 825.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after acquiring an additional 66 shares during the last quarter. DiNuzzo Private Wealth Inc. grew its stake in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after buying an additional 61 shares in the last quarter. HighMark Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after acquiring an additional 45 shares during the last quarter. Finally, Howard Hughes Medical Institute bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth about $33,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Frederick M. Lowery sold 6,913 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $597.68, for a total value of $4,131,761.84. Following the completion of the sale, the executive vice president owned 14,367 shares in the company, valued at $8,586,868.56. The trade was a 32.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 149,271 shares of company stock worth $86,507,282. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $615.60 on Tuesday. The stock has a market cap of $231.29 billion, a PE ratio of 35.56, a price-to-earnings-growth ratio of 4.07 and a beta of 0.91. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $628.08. The business’s fifty day moving average price is $582.36 and its two-hundred day moving average price is $519.52.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock repurchase program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Friday. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective on the stock in a report on Sunday, December 7th. Finally, Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $625.47.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.